check_circleStudy Completed

Bayer Identifier:

10916

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

Not Available

EU CT Number:

Not Available
BAY 43 9006 in combination with doxorubicin chemotherapy in patients

Trial purpose

Primary objective: To define the safety profile of continuously administered
sorafenib in combination with 3-weekly administrations of doxorubicin in subjects with advanced, refractory solid tumors;
Secondary objectives were
• To evaluate the pharmacokinetics and pharmacodynamics of sorafenib in combination with doxorubicin and vice versa;
• To determine the objective tumor response rate including complete and partial response rates based on WHO criteria.

Key Participants Requirements

Sex

N/A

Age

33 - 78 Years
  • -

  • -

Trial summary

Enrollment Goal
54
Trial Dates
September 2002 - March 2008
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteer
No

Trial design

Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.Click here and search for websynopsis information provided by Bayer